DTaP Makers Cannot Claim Superiority Based on Antigen Number, FDA Says
Executive Summary
FDA recently warned all diphtheria, tetanus toxoids and acellular pertussis vaccine manufacturers of making claims of clinical superiority based on the number of pertussis components in a vaccine.